Artimplant AB clears royalty rights for Artelon®

Artimplant AB clears royalty rights for Artelon®

Västra Frölunda, Sweden, September 26, 2007
The biomaterials company Artimplant clears royalty rights for the biomaterial
Artelon®. With effect from January 1, 2007 this improves Artimplant's margin on
license income from product sales by five percentage points.

Artimplant AB clears royalty rights for the basic patent for the biomaterial
platform Artelon®. The present holder, Polyrand AB, receives SEK 2,750,000 to
clear the agreement containing the rights. With effect from January 1, 2007 this
improves Artimplant's margin on license income from product sales by five
percentage points. Artimplant currently receives license income from Small Bone
Innovations, Inc. in respect of sales of Artelon® Spacer and from Biomet Sports
Medicine in respect of sales of SportMesh™ Soft Tissue Reinforcement. The
payment to Polyrand will be charged to Artimplant's cash reserves and will be
recorded as a patent investment during the fourth quarter of 2007.

Polyrand AB was founded by the late Per Flodin, the person behind the basic
patent for Artelon®. Per Flodin was professor emeritus in polymer technology at
Chalmers University of Technology.

For further information, please contact:
Hans Rosén, CEO, phone +46 (0)31-746 56 00, +46 (0)708 58 34 70,
hans.rosen@artimplant.com

Lars-Johan Cederbrant, CFO, phone +46 (0)31-746 56 54, +46 (0)703 01 68 54,
lars-johan.cederbrant@artimplant.com

Web site: www.artimplant.com

About Artimplant
Artimplant is a biomaterials company focused on solutions to problems in
orthopedic and oral surgery. We restore health through the development,
production, and marketing of degradable implants that regenerate body functions
and improve quality of life. Our products, made from Artelon®, meet unmet
clinical needs and are marketed in a growing number of therapy areas. Artimplant
produces implants for treatment of osteoarthritis in hands and feet, for
shoulder and other soft tissue injuries as well as oral applications.

Artimplant is a public company listed on the OMX Nordic Exchange Stockholm in
the Small Cap segment and in the healthcare sector.


Forward-looking statements
This press release contains forward-looking statements as defined in the U.S.
Private Securities Litigation Reform Act of 1995. Readers are cautioned not to
place undue reliance on these forward-looking statements. Actual results may
differ materially from those indicated by these forward-looking statements as a
result of risks and uncertainties impacting the Company's business including
increased competition; the ability of the Company to expand its operations and
to attract and retain qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from time to time in the
Company's filings.